An estimated 234,030 new cases of lung cancer will be diagnosed in the United States in 2018. As the major type, non-small cell lung cancer (NSCLC) represents about 80% to 85% of lung cancers. It is therefore critical for oncology healthcare practitioners (HCPs) to be able to appropriately utilize novel treatment options that can target locally advanced or metastatic NSCLC. The discovery of anaplastic lymphoma kinase (ALK) rearrangements as oncogenic driver mutations has resulted in the development of targeted tyrosine kinase inhibitors against ALK (ALKis). The ALKis have shifted the standard of care for patients with metastatic NSCLC harboring specific ALK rearrangements (designated ALK+ NSCLC). Therefore, for the benefit of patients with this devastating disease, oncology HCPs require timely, comprehensive continuing education that can guide them in safely and effectively incorporating these novel therapeutic options into their practices.

Release date: Monday, April 15, 2019 

Expiration date: April 15, 2020.

OncologyConsults.com is a learning portal that will address knowledge, competence and clinical practice gaps among clinicians who care for patients with cancers.

Weblink:
https://www.oncologyconsults.com/Home/CEData?id=793

1. Describe the clinical relevance of ALK genetic testing on treatment-decision-making in NSCLC and the rationale for ALKi therapy.
2. Assess the efficacy, safety, and clinical utility of 1st-line ALKis in patients with ALK+ NSCLC.
3. Evaluate subsequent line treatment options upon acquired resistance to ALKi.
4. Develop individualized treatment protocols for patients with ALK+ NSCLC based on the most up-to- date clinical data regarding first/subsequent lines of treatment.